The study, presented at the American Society for Clinical Oncology’s annual meeting, scrutinized patients on three chemotherapy regimens that were not supported by evidence from prior clinical studies or clinical practice guidelines.
The drugs were bevacizumab, costing $1.3 million per patient, capecitabine, costing more than $600,000, and panitumumab, costing almost $70,000. As costs of cancer care continue to mount, researchers predicted there will be increasing pressure to base treatment decisions on solid clinical evidence.
Read the Endo Nurse report on colon cancer.
Related Articles on Colon Cancer:
Poll Finds Low Follow-up Screening Rates for Colon Cancer
Mouth Lining Examination May Detect Colon Cancer Risk
Nearly One-Third of Target Population Unscreened for Colon Cancer
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
